Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 24 of the 42 sources its claims cite were checked for support.
Abstract
BACKGROUND: High triglyceride levels are associated with increased cardiovascular risk, but whether reductions in these levels would lower the incidence of cardiovascular events is uncertain. Pemafibrate, a selective peroxisome proliferator-activated receptor α modulator, reduces triglyceride levels and improves other lipid levels. METHODS: In a multinational, double-blind, randomized, controlled trial, we assigned patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia (triglyceride level, 200 to 499 mg per deciliter), and high-density lipoprotein (HDL) cholesterol levels of 40 mg per deciliter or lower to receive pemafibrate (0.2-mg tablets twice daily) or matching placebo. Eligible patients were receiving guideline-directed lipid-lowering therapy or could not receive statin therapy without adverse effects and had low-density lipoprotein (LDL) cholesterol levels of 100 mg per deciliter or lower. The primary efficacy end point was a composite of nonfatal myocardial infarction, ischemic stroke, coronary revascularization, or death from cardiovascular causes. RESULTS: Among 10,497 patients (66.9% with previous cardiovascular disease), the median baseline fasting triglyceride level was 271 mg per deciliter, HDL cholesterol level 33 mg per deciliter, and LDL cholesterol level 78 mg per deciliter. The median follow-up was 3.4 years. As compared with placebo, the effects of pemafibrate on lipid levels at 4 months were -26.2% for triglycerides, -25.8% for very-low-density lipoprotein (VLDL) cholesterol, -25.6% for remnant cholesterol (cholesterol transported in triglyceride-rich lipoproteins after lipolysis and lipoprotein remodeling), -27.6% for apolipoprotein C-III, and 4.8% for apolipoprotein B. A primary end-point event occurred in 572 patients in the pemafibrate group and in 560 of those in the placebo group (hazard ratio, 1.03; 95% confidence interval, 0.91 to 1.15), with no apparent effect modification in any prespecified subgroup. The overall incidence of serious adverse events did not differ significantly between the groups, but pemafibrate was associated with a higher incidence of adverse renal events and venous thromboembolism and a lower incidence of nonalcoholic fatty liver disease. CONCLUSIONS: Among patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia, and low HDL and LDL cholesterol levels, the incidence of cardiovascular events was not lower among those who received pemafibrate than among those who received placebo, although pemafibrate lowered triglyceride, VLDL cholesterol, remnant cholesterol, and apolipoprotein C-III levels. (Funded by the Kowa Research Institute; PROMINENT ClinicalTrials.gov number, NCT03071692.).
Overview
CoChat Summary
TL;DR
In the PROMINENT trial, pemafibrate lowered triglyceride and remnant cholesterol levels but did not reduce cardiovascular events among patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia, low HDL cholesterol, and controlled LDL cholesterol. The trial was stopped early for futility, and pemafibrate was associated with more renal adverse events and venous thromboembolism.
Key findings
- Among 10,497 patients, a primary end-point event occurred in 572 patients in the pemafibrate group and 560 in the placebo group (hazard ratio, 1.03; 95% CI, 0.91 to 1.15; P=0.67), with no apparent effect modification in any prespecified subgroup.
- At 4 months, the relative between-group differences were −26.2% for triglycerides, −25.8% for VLDL cholesterol, −25.6% for remnant cholesterol, and −27.6% for apolipoprotein C-III; apolipoprotein B increased by 4.8%.
- Serious adverse events did not differ significantly overall (1970 vs. 1914; hazard ratio, 1.04; 95% CI, 0.98 to 1.11; P=0.23), but pemafibrate was associated with higher renal adverse events (1463 vs. 1347; hazard ratio, 1.12; 95% CI, 1.04 to 1.20; P=0.004) and venous thromboembolism (71 vs. 35; hazard ratio, 2.05; 95% CI, 1.35 to 3.17; P<0.001), and lower nonalcoholic fatty liver disease (155 vs. 200; hazard ratio, 0.78; 95% CI, 0.63 to 0.96; P=0.02).
Methods
- Multinational, double-blind, randomized, placebo-controlled, event-driven trial conducted at 876 clinical sites in 24 countries; 10,497 patients composed the intention-to-treat population after 41 randomized patients were excluded for Good Clinical Practice violations.
- Eligible patients had type 2 diabetes, fasting triglyceride levels of 200 to 499 mg per deciliter, HDL cholesterol ≤40 mg per deciliter, and LDL cholesterol ≤100 mg per deciliter if they could not receive statins without adverse effects; patients were randomly assigned 1:1 to pemafibrate 0.2-mg tablets twice daily or matching placebo, with median follow-up of 3.4 years.
- The primary efficacy end point was a composite of nonfatal myocardial infarction, ischemic stroke, coronary revascularization, or death from cardiovascular causes; analysis used a likelihood-ratio test based on a proportional-hazards model stratified by sex, history of cardiovascular disease, and baseline statin use, with analysis of covariance for lipid changes.
Limitations
- The paper states that the data cannot rule out the possibility that observed increases in apolipoprotein B and LDL cholesterol levels in the pemafibrate group negated any benefit of reduction in triglyceride or remnant cholesterol levels.
- The trial was terminated early for futility after 75% of the target number of events had accrued, with median follow-up of 3.4 years; the text notes this termination but does not frame it as a limitation.
- Evident from the text: the trial population was 27.5% women and predominantly white (85.4% in the pemafibrate group and 86.4% in the placebo group), which may limit generalizability; the paper does not state this as a limitation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 1 Not valid · 6 Not checked · 62 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The data from the PROMINENT trial are consistent with increased efficiency in conversion of triglyceride-rich lipoprotein remnants to LDL rather than their removal by the liver. 21”
What the sources say
- Disputedcites [21] 21. Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies - a consensus statement from the European Atherosclerosis Society. Eur Heart J 2021; 42: 4791-806. sourceExperimental — accuracy not yet measured
The “Stimulating lipolysis” section says further insights were awaited from PROMINENT, rather than reporting data from it. The paper discusses conversion of remnants to LDL as a possible consequence of more efficient lipolysis, but does not attribute that finding to PROMINENT. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“With the exception of the FIELD trial, all these trials involved patients who were receiving statins.”
What the sources say
- Partly supportedcites [2] 2. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA 2020; 324: 2268-80. sourceExperimental — accuracy not yet measured
The Study Population section (p. 3) says participants in this trial were required to receive statins, supporting the claim for the STRENGTH trial. It does not establish that every other trial under discussion involved statin-treated patients or that FIELD was the sole exception. (LLM, conf=0.84)
- Partly supportedcites [4] 4. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67. sourceExperimental — accuracy not yet measured
The AIM-HIGH paper reports statin use in its own trial: Table 1, reproduced in the Discussion passage, shows baseline use in 94.4% and 92.8% of the two groups. Our copy does not establish that all the other trials referred to by the citing sentence involved patients receiving statins, or that FIELD was the exception. (LLM, conf=0.83)
- Partly supportedcites [6] 6. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 156374. sourceExperimental — accuracy not yet measured
The Methods (Study Design; page not available) say ACCORD Lipid assigned patients to simvastatin plus fenofibrate or placebo, supporting the claim for this trial. The Discussion (page not available) contrasts ACCORD with FIELD’s statin-therapy drop-in, but does not establish that all the other trials mentioned involved patients receiving statins. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, a previous trial of niacin 4 and two previous trials of fenofibrate 5,6 showed no significant decrease in cardiovascular risk, although triglyceride levels were lowered by 26%, 29%, and 26%, respectively.”
What the sources say
- Partly supportedcites [4] 4. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67. sourceExperimental — accuracy not yet measured
The Discussion reports no significant reduction in cardiovascular events with extended-release niacin added to intensive statin therapy. However, the Lipid Levels section reports a 28.6% triglyceride decrease at two years in the niacin group, not 26%; Table 2 also gives no 26% decrease at years one or three. Our copy does not provide page numbers for these passages. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“although the findings regarding the latter effect of PPARα agonism are less consistent than those regarding increases in the activity of lipoprotein lipase. 17-19”
What the sources say
- Not checked — no full text of the sourcecites [17] 17. Ginsberg HN. Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives. Am J Med 1987; 83: 66-70. source
- Not checked — no full text of the sourcecites [18] 18. Watts GF, Barrett PH, Ji J, et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003; 52: 803-11. source
- Supportedcites [19] 19. Fabbrini E, Mohammed BS, Korenblat KM, et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010; 95: 2727-35. source
The Discussion (page unavailable) says fibrates differ in their effects on VLDL secretion and clearance, while describing stimulation of lipoprotein lipase activity as a known fibrate effect. The Results likewise show that fenofibrate reduced VLDL-apoB secretion but did not change hepatic VLDL-TG secretion. Together, these passages support the cited comparison in consistency. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Thus, our data further highlight the complexity of lipid mediators of residual risk among patients with insulin resistance who are receiving statin therapy. 6,23-25”
What the sources say
- Supportedcites [6] 6. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 156374. source
The cited ACCORD Lipid paper provides background for the citing authors’ conclusion, rather than evidence about their own PROMINENT data. Its Results (Plasma Lipids and Clinical Outcomes; page unavailable) report lipid changes with fenofibrate added to simvastatin but no significant overall reduction in cardiovascular events; the Discussion describes a possible benefit in a dyslipidemic subgroup. These findings support the point that lipid-related residual risk in statin-treated patients with type 2 diabetes is complex. (LLM, conf=0.85)
- Supportedcites [23] 23. Elam MB, Ginsberg HN, Lovato LC, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol 2017; 2: 370-80. source
The reference supports the cited background point, not the citing authors’ statement about their own PROMINENT data. The Introduction describes uncertain cardiovascular benefit from targeting triglycerides and HDL-C in statin-treated patients with type 2 diabetes; the Discussion describes mixed trial results, and the Results report a neutral overall fenofibrate effect but possible benefit in a dyslipidemic subgroup. (LLM, conf=0.88)
- Partly supportedcites [24] 24. Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab 2019; 21: 366-71. sourceExperimental — accuracy not yet measured
The Discussion reports that triglyceride levels were associated with residual cardiovascular events in statin-treated patients with diabetes despite controlled LDL cholesterol, supporting the background point about lipid-related residual risk. The study concerns patients with diabetes, not the broader population of patients with insulin resistance. The citing authors’ statement about what their own data highlight is not attributed to this source. (LLM, conf=0.82)
- Partly supportedcites [25] 25. Zhao Y, Xiang P, Coll B, López JAG, Wong ND. Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease. J Diabetes Complications 2021; 35: 107767. Copyright © 2022 Massachusetts Medical Society. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report residual ASCVD risk in statin-treated patients with diabetes and identify lipoprotein(a) as a predictor of recurrent events. This supports a role for lipid-related risk, but the paper studies diabetes rather than insulin resistance broadly and does not establish lipid mediation of that residual risk. The citing sentence’s reference to “our data” is the citing authors’ own conclusion, not a claim about this source. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
44 more claims
Create a free account to see all 81 claims and every source verdict.
- It may state two separate claims as one. 16
- Probably not a substantial claim. 22
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At a median follow-up of 3.4 years, pemafibrate lowered triglycerides by − 26%, VLDL by − 26%, remnant cholesterol by − 26% and ApoC-III by − 28% compared with placebo.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [180]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the PROMINENT trial, in people with type 2 diabetes and elevated triglycerides (≥200 mg/dL and low HDL [≤40 mg/dL]), pemafibrate 0.2 mg twice daily reduced triglycerides by 26% but did not reduce the risk of the primary outcome of nonfatal MI, nonfatal stroke, hospitalization for unplanned coronary revascularization, or cardiovascular death (151).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [151]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, pemafibrate did not significantly reduce the risk of MACE (HR 1.03, 95% CI 0.91–1.15).”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [180]
The cited source says what the claim attributes to it.
In the citing paper
“Although pemafibrate significantly reduced TGs (–26.2%), VLDL-C, and remnant cholesterol, it did not reduce MACE compared to placebo, likely due to a lack of effect on apoB-containing particle number and modest increases in LDL-C [64, 65].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [64]
The cited source says what the claim attributes to it.
In the citing paper
“Although pemafibrate significantly reduced TGs (–26.2%), VLDL-C, and remnant cholesterol, it did not reduce MACE compared to placebo, likely due to a lack of effect on apoB-containing particle number and modest increases in LDL-C [64, 65].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [64]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Effects on Lipid Levels and Other Key Biomarkers · p. 8
“Pemafibrate, as compared with placebo, also had similar effects on changes from baseline to 4 months and over time on levels of measured very-low-density lipoprotein (VLDL) cholesterol (-25.8%)”
§ Effects on Lipid Levels and Other Key Biomarkers · p. 7
“| VLDL cholesterol level, calculated - mg/dl‡ | VLDL cholesterol level, calculated - mg/dl‡ | VLDL cholesterol level, calculated - mg/dl‡ | VLDL cholesterol level, calculated - mg/dl‡ |”
Citations
Cites
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Self-citationNicholls, S. J., Lincoff, A. M., Garcia, M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., et al. (2020) · JAMA · doi:10.1001/jama.2020.22258 · Cited by 1,028
Self-citationGinsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
Self-citationEffects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927
Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319
Self-citationCombination lipid therapy in type 2 diabetes
(2010) · New England Journal of Medicine · doi:10.1056/nejmc1006407 · Cited by 245
Cited by
Items 201–300 of 728
Bilgic, S., Pencina, K. M., Pencina, M. J., Cole, J., Dufresne, L., Thanassoulis, G., & Sniderman, A. D. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.321165 · Cited by 15
Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia
Hooper, A. J., Bell, D. A., & Burnett, J. R. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2408369 · Cited by 17
“The PROMINENT trial of pemafibrate in patients with T2DM and mild-moderate HTG showed a lack of effect on cardiovascular events; while patients demonstrated a 26% reduction in TG, LDL-cholesterol increased by 11%, potentially offsetting any benefit [25].”
Jie, H., Zhang, J., Wu, S., Yu, L., Li, S., Dong, B., & Feng, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1503824 · Cited by 20
Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.5 · Cited by 17
Glycemic Targets and Prevention of Complications
Tsushima, Y., & Galloway, N. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae776 · Cited by 21
Joint Associations of APOC3 and LDL-C–Lowering Variants With the Risk of Coronary Heart Disease
Wang, W., Li, R. P., Song, Z., Huang, N., Huang, T., Hua, X., & Tang, Y.-D. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0195 · Cited by 16
Schuitema, P. C. E., Visseren, F. L. J., Nordestgaard, B. G., Teraa, M., van der Meer, M. G., Ruigrok, Y. M., Onland‐Moret, N. C., & Koopal, C. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120411 · Cited by 21
Self-citationRui, S., Xiao, F., Li, Q., Yang, M.-L., Dai, L., Yu, S., Zhang, X., Jiang, X., Ahn, S., Wang, W., et al. (2025) · Burns & Trauma · doi:10.1093/burnst/tkaf063 · Cited by 14
How to Handle Elevated Triglycerides: Life after PROMINENT
Pirillo, A., & Catapano, A. L. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01175-2 · Cited by 16
Rosenson, R. S., Rader, D. J., Ali, S., Banerjee, P., McGinniss, J., & Pordy, R. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07567-z · Cited by 13
“…hypertriglyceridemia, and low HDL and LDL-C levels, pemafibrate, a selective peroxisome proliferator-activated receptor alpha modulator, reduced median fasting TG levels by 31.1%, VLDL cholesterol by 35.0%, remnant cholesterol by 43.6%, and ApoCIII by 27.8% from baseline to 4 months [18].”
InfluentialYamashita, S., Hirano, T., Shimano, H., Tsukamoto, K., Yoshida, M., & Yoshida, H. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14227 · Cited by 14
“66 The apparent increase in serum creatinine, which is a result of PPAR α agonism, can be attributed to increased creatinine production and decreased intraglo-merular pressure due to the suppression of prostaglandin production in renal tissue.”
Toth, P. P., & Banach, M. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae057 · Cited by 17
“38,39 Based on a variety of studies using fenofibrate 40 and pemafibrate, 41 fibrate therapy does not impact risk for ASCVD-related events.”
BackgroundPapafaklis, M. I., Koros, R., Tsigkas, G., Καρανάσος, Α., Μούλιας, Α., & Davlouros, P. A. (2024) · Biomedicines · doi:10.3390/biomedicines12112435 · Cited by 21
“…setting, in the randomized PROMINENT (The Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes) trial, the administration of pemafibrate did not achieve the primary efficacy endpoint of reducing cardiovascular events during approximately 3 years [87].”
From lipotoxicity to pan-lipotoxicity
Cheng, Y., Shao, S., Wang, Z., Guan, Q., Li, H., Liu, G., Zhang, H., Fan, X., & Zhao, J. (2025) · Cell Discovery · doi:10.1038/s41421-025-00787-z · Cited by 14
Lan, N. S. R., Bell, D. A., Watts, G. F., & Fegan, P. G. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000790 · Cited by 13
Mszar, R., Bart, S., Sakers, A. P., Soffer, D. E., & Karalis, D. G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041382 · Cited by 17
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 15
Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease
Tsimikas, S. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01345-4 · Cited by 16
“…group were imputed under the MAR assumption [4] For triglyceride, Hodges-Lehmann estimate of the location shift with 95% CI were the overall estimates combined from all 100 tests omega-3 fatty acids respectively, failed to show ASCVD risk reduction despite lowering triglycerides [ 49 , 50 ].”
Marston, N., Bergmark, B. A., Prohaska, T. A., Moura, F. A., Zimerman, A., Alexander, V. J., Kang, Y. M., Weinland, J., Ran, X., Murphy, S. A., et al. (2026) · Circulation · doi:10.1161/circulationaha.126.080012 · Cited by 22
Self-citationВладиславович, Е. М., & Arutyunov, G. P. (2023) · Diseases · doi:10.3390/diseases11040140 · Cited by 14
Kim, N. H., Kim, J. Y., Choi, J., & Kim, S. G. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad090 · Cited by 17
Yang, R., Zhang, J., Yu, X., Yang, G., & Cai, J. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae001 · Cited by 12
Papantoniou, E., Arvanitakis, K., Markakis, K., Papadakos, S. P., Tsachouridou, Ο., Popovic, D. S., Koufakis, T., Germanidis, G. S., & Kotsa, K. (2024) · Life · doi:10.3390/life14040449 · Cited by 19
“…fibrates failed to reduce the incidence of cardiovascular events of more than 10,000 patients with increased ASCVD risk in the PROMINENT study that was conducted with participants from the general population; therefore, similar long-scale studies in the HIV population seem to be imperative [211].”
Special aspects of cholesterol metabolism in women
Gouni‐Berthold, I., & Laufs, U. (2024) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2024.0063 · Cited by 20
Sumida, Y., Toyoda, H., Yasuda, S., Kimoto, S., Sakamoto, K., Nakade, Y., Ito, K., Osonoi, T., & Yoneda, M. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64896 · Cited by 16
“These results are consistent with the findings of a recent RCT investigating pemafibrate versus placebo (PROMINENT trial), which reported an improvement in TG, very-low-density lipoprotein, remnant cholesterol, and apolipoprotein C-III levels with pemafibrate 23) .”
MethodResultAtherogenic low-density lipoprotein and cardiovascular risk
Hernando‐Redondo, J., Castañer, O., & Fitó, M. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000963 · Cited by 13
Wadström, B. N., Wulff, A. B., Pedersen, K. M., & Nordestgaard, B. G. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvae222 · Cited by 13
Self-citationRiis, J., Nordestgaard, B. G., & Afzal, S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf092 · Cited by 15
Self-citationSEA 2024 Standards for Global Control of Vascular Risk
Mostaza, J. M., Pintó, X., Armario, P., Masana, L., Real, J. T., Valdivielso, P., Arrobas-Velilla, T., Baeza‐Trinidad, R., Calmarza, P., Cebollada, J., et al. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2024.06.001 · Cited by 18
Khan, M. S., Ghumman, G. M., Baqi, A., Shah, J., Aziz, M., Mir, T., Tahir, A., Katragadda, S., Singh, H., Taleb, M., et al. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00593-6 · Cited by 11
“These triglyceride-rich lipoprotein remnants get converted to LDL particles rather than their removal from the liver (as was shown by the results of the PROMINENT trial) [25].”
BackgroundMethodInfluentialHenry, D., Baugé, E., Hennuyer, N., Ory, K., Derudas, B., Vallez, E., Deprince, A., Lefèbvre, P., Haas, J. T., Staels, B., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adj8192 · Cited by 14
Licata, A., Russo, G. T., Giandalia, A., Cammilleri, M., Asero, C., & Cacciola, I. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030558 · Cited by 14
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?
Wadström, B. N., Wulff, A. B., Pedersen, K. M., & Nordestgaard, B. G. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01153-8 · Cited by 13
Self-citationHIV-associated dyslipidemia: pathogenesis and its management
Wan, Z., Dai, B., Zhu, X., Huang, Y., & Zhu, B. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002879 · Cited by 11
Miller, M., Bhatt, D. L., Brinton, E. A., Jacobson, T. A., Steg, P. G., Pineda, A. L., Ketchum, S. B., Doyle, R. T., Tardif, J.-C., & Ballantyne, C. M. (2023) · European Heart Journal Open · doi:10.1093/ehjopen/oead114 · Cited by 11
Self-citationIzumihara, R., Nomoto, H., Kito, K., Yamauchi, Y., Omori, K., Shibayama, Y., Yanagiya, S., Miya, A., Kameda, H., Cho, K. Y., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0370 · Cited by 13
Masuyama, S., Mizui, M., Morita, M., Shigeki, T., Kato, H., Yamamoto, T., Sakaguchi, Y., Inoue, K., Namba‐Hamano, T., Matsui, I., et al. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110357 · Cited by 14
Remnant Cholesterol: Should it be a Target for Prevention of ASCVD?
Doi, T., Langsted, A., & Nordestgaard, B. G. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01288-w · Cited by 13
“%) and apolipoprotein B increased by 0.05 g/L (5 mg/dL; 5%), respectively [13].”
InfluentialSelf-citationHirano, T. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.13983 · Cited by 11
“eride, total-C, and high-density lipoprotein cholesterol from the original paper.(1)”
BackgroundLeiherer, A., Muendlein, A., Saely, C. H., Geiger, K. D., Brandtner, E., Heinzle, C. F., Gaenger, S., Mink, S., Laaksonen, R., Fraunberger, P., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196151 · Cited by 10
“However, given the poor role fibrates have demonstrated in reducing cardiovascular risk [46], it seems questionable whether fibrates might become useful as a ceramide-modulating drug class for lowering CVD risk.”
BackgroundTriglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Regemorter, E. V., Jadoul, M., & Gillion, V. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2216470 · Cited by 12
Management of dyslipidaemia in patients with comorbidities—facing the challenge
Frühwald, L., Fasching, P., Dobrev, D., Kaski, J. C., Borghi, C., Waßmann, S., Huber, K., Semb, A. G., Agewall, S., & Drexel, H. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae095 · Cited by 11
“72 Fibrates are associated with a reversible decline in renal function and an increase in transaminase levels.”
Natural compounds regulating fatty acid oxidation in the treatment of diabetic kidney disease
Sun, J., Yin, C., Li, Z., Gao, X., Li, S., Gao, H., An, Y., Liu, P., & Na, L. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1669557 · Cited by 17
Inflammatory Effects of Triglycerides
Kraaijenhof, J. M., & Stroes, E. S. G. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.04.005 · Cited by 13
“On the other hand, recent data from the PROMINENT (Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes) study emphasized that solely enhancing the metabolism of large triglyceride particles into atherogenic but smaller triglyceride-rich remnants and lowdensity lipoprotein-…”
BackgroundMueller, P. A., Bergstrom, P., Rosário, S., Heard, M. E., & Pamir, N. (2024) · Journal of Nutrition · doi:10.1016/j.tjnut.2024.01.007 · Cited by 12
Hansen, M. K., Mortensen, M. B., Olesen, K. K. W., Thrane, P. G., Thomsen, R. W., & Mæng, M. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae119 · Cited by 12
Phospholipid biomarkers of coronary heart disease
Morita, S. (2024) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-024-00344-y · Cited by 10
“In fact, a potent selective peroxisome proliferator-activated receptor α modulator, pemafibrate, is ineffective in reducing the incidence of cardiovascular events despite the marked reduction in TG levels [28, 29].”
BackgroundWon, K., Kim, H. J., Cho, J. H., Lee, S. Y., Her, A., Kim, B., Joo, H. J., Park, Y., Chang, K., Song, Y. B., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-60999-3 · Cited by 14
“…mild-to-moderate hypertriglyceridemia, and low HDL and LDL cholesterol levels, the primary endpoint of non-fatal MI, ischemic stroke, coronary revascularization, or death from cardiovascular causes was not lower among patients who received pemafibrate than among those who received placebo 25 .”
BackgroundEffect of Pemafibrate on Diabetic Foot Ulceration and Gangrene
Marinho, L., Everett, B. M., Aday, A. W., Visseren, F. L. J., MacFadyen, J. G., Zaharris, E., Plutzky, J., Santos, R. D., Libby, P., Fruchart, J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.028 · Cited by 11
Self-citationMaidman, S. D., Hegele, R. A., & Rosenson, R. S. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01258-8 · Cited by 14
“…vascular Outcomes by Reducing Triglycerides in Patients with Diabetes) trial similarly did not detect a difference in ASCVD events despite significant lowering in TG, VLDL cholesterol, remnant cholesterol (measured by subtracting LDL cholesterol from non-HDL cholesterol), and apo C-III levels [36].”
InfluentialRecent Advances in the Management of Dyslipidemia: A Systematic Review
Feng, H. J. X., Yousaf, A., Moon, J., Ramiz, A., Krishma, U., & Pemminati, S. (2025) · Cureus · doi:10.7759/cureus.81034 · Cited by 22
Metabolic syndrome with mortality and major adverse cardiovascular events in an elderly population
Karn, S. K., Zhao, F., Xu, Y., Zhang, Y., Zeng, C., Shaikh, I. I., Singh, S., & Feng, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1570191 · Cited by 14
Balling, M., Roepstorff, O. G., Gerds, T. A., Varbo, A., Mortensen, M. B., Langsted, A., Nordestgaard, B. G., & Afzal, S. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120471 · Cited by 14
Self-citationInflammation contributes to cardiovascular risk in patients receiving statin therapy
Tardif, J., & Samuel, M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00454-3 · Cited by 12
Hirano, T., & Ito, Y. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14013 · Cited by 15
Gupta, K., Hirsch, J. R., Kalsi, J., Patel, V., Gad, M. M., & Virani, S. S. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01079-7 · Cited by 9
Amigó, N., Torné, P., Nordestgaard, L. T., Barbagallo, F. D. G., Merino, C., Magni, P., González-Lleó, A. M., Andreychuk, N., Catapano, A. L., Masana, L., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178284 · Cited by 10
“The lack of efficacy has been attributed to the null effect on total apoB-containing particles due to an increase in LDL levels [15].”
Kraler, S. C., Liberale, L., Tirandi, A., Moriero, M., Wang, Y., Farag, M., Carbone, F., Bertolotto, M. B., Pusterla, V., Ramoni, D., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf979 · Cited by 12
“15,16 52–55 This discrepancy may be due to differences in study design, distinct patient populations (real-world data vs selected trial populations), different in-/exclusion criteria, and post-ACS settings.”
Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities
Александровна, П. В., & Okovityi, S. V. (2026) · Biomedicines · doi:10.3390/biomedicines14040909 · Cited by 10
Bilgic, S., & Sniderman, A. D. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001100 · Cited by 10
Bibliometric analysis of residual cardiovascular risk: trends and frontiers
Wang, L., Wang, S., Song, C., Yu, Y., Jiang, Y., Wang, Y., & Li, X. (2023) · Journal of Health Population and Nutrition · doi:10.1186/s41043-023-00478-z · Cited by 12
“More importantly, the recently held AHA 2022 announced the results of the PROMINENT trial: pemafibrate reduced TG levels in patients with type 2 diabetes, but did not reduce the risk of cardiovascular events and death [90].”
BackgroundIn the Beginning, Lipoproteins Cross the Endothelial Barrier
Goldberg, I. J., Cabodevilla, A. G., & Younis, W. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22017 · Cited by 10
“In addition, one interpretation of the recent PROMINENT study is that fibrate conversion of VLDL to LDL confirmed that these two lipoproteins were equally atherogenic 42) .”
BackgroundBentanachs, R., Miró, L., Sánchez, R. M., Ramírez-Carrasco, P., Amat, C., Alegret, M., Pérez, A., Roglans, N., & Laguna, J. C. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117067 · Cited by 11
“PemA treatment was associated with a lower incidence of MASLD in a recently published multinational, double-blind, randomized, controlled trial (RCT) [14].”
InfluentialDai, W., Lv, Q., Li, Q., Fu, L., Zhang, Y., Zhang, Y., Liu, L., Tanigawa, R., Kunitomi, K., Kamei, R., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64112 · Cited by 9
“In the PROMINENT trial, significantly fewer total hepatic events and investigator-reported cases of nonalcoholic fatty liver disease were observed 15) .”
VLDL triglycerides and cholesterol in non-alcoholic fatty liver disease and myocardial infarction
Kyhl, L. K., Nordestgaard, B. G., Tybjærg‐Hansen, A., Smith, G. D., & Nielsen, S. F. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119094 · Cited by 10
Self-citationApproach to Lipid Management in the Patient With Diabetes
Kim, S. J., & Subramanian, S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf018 · Cited by 14
Obesity phenotypes and atherogenic dyslipidemias
Choe, H. J., Almas, T., Neeland, I. J., Lim, S. K., & Després, J. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70151 · Cited by 18
Tokgözoğlu, L. S., Pirillo, A., & Catapano, A. L. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad485 · Cited by 9
Bakbak, E., Krishnaraj, A., Bhatt, D. L., Quan, A., Park, B., Bakbak, A. I., Bari, B., Terenzi, K. A., Pan, Y., Fry, E. J., et al. (2024) · Med · doi:10.1016/j.medj.2024.03.009 · Cited by 11
Self-citationWright, J., & Subramanian, S. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.03.005 · Cited by 12
Hong, S., Kim, K., Han, K., & Park, C. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02353-5 · Cited by 11
“However, a recent study with pemafibrate did not indicate any beneficial effects on ASCVD in individuals with these factors [13].”
BackgroundResultInfluentialTriglycerides: the past, the present, and the future
Braunwald, E. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae515 · Cited by 15
Fibrates: one more lost paradise in lipid treatment
Drexel, H., Saely, C. H., & Agewall, S. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac072 · Cited by 9
Santos, R. D. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad064 · Cited by 10
Self-citationPandey, R. K., Jan, M., Mohammad, A., Jawaid, K. A., Naveed, M., Abid, M. A., Amir, A. B., Ahmed, S., Safiullah, M., Bhatti, M. I., et al. (2025) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.70134 · Cited by 9
“For instance, lipid-modifying agents such as fenofibrate and pe-mafibrate primarily lower triglycerides but have shown limited cardiovascular benefit, with only a non-significant trend toward risk reduction in large outcome trials [43, 44].”
Management and Pharmacological Treatment of Peripheral Arterial Disease
Leatham, S. J., Winckel, K., & Guzman, K. R. D. (2024) · Journal of Pharmacy Practice · doi:10.1177/08971900241250084 · Cited by 10
Akiyama, T., Ikegami, R., Kubota, N., Takano, T., Yoneyama, S., Okubo, T., Hoyano, M., Ozaki, K., & Inomata, T. (2024) · Circulation Journal · doi:10.1253/circj.cj-24-0242 · Cited by 9
New Approaches to Lipoproteins for the Prevention of Cardiovascular Events
Fujino, M., Giovanni, G. D., & Nicholls, S. J. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22031 · Cited by 8
“The PROMINENT trial 62) , a multinational randomized controlled study involving 10,497 patients with type 2 diabetes, hypertriglyceridemia (200-499 mg/dL), and low high-density lipoprotein cholesterol (HDL-C) (≤ 40 mg/dL), compared the effects of pemafibrate and placebo.”
Small nerve fibre damage and cardiac autonomic dysfunction in patients with hypertriglyceridaemia
Bashir, B., Pasha, R., Kamath, A., Malik, R. A., Ferdousi, M., & Soran, H. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119186 · Cited by 8
Self-citationApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?
Biolo, M., Galimberti, F., Portinari, C., Bertocco, S., Tosin, P., Casula, M., Previato, L., Zambon, S., Simioni, P., & Zambon, A. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01315-w · Cited by 9
“Notably, the recent results of the PROMINENT trial suggest that any ASCVD benefit from TG and ApoC-III reduction might have been diminished by unfavourable change in LDL-cholesterol or ApoB levels with pemafi - brate [43].”
Franczyk, B., Młynarska, E., Rysz-Górzyńska, M., Gluba-Brzózka, A., Rysz, J., Sheth, S., Surma, S., Banach, M., & Toth, P. P. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101068 · Cited by 10
“More recently, the PROMINENT trial evaluated pemafibrate, a selective PPAR α modulator, in over 10,000 patients with type 2 diabetes, low HDL-C ( ≤ 40 mg/dL), and elevated triglycerides (200 – 499 mg/dL), all of whom were on statin therapy [159].”
Lipoprotein(a) and Venous Thromboembolism: Association, Causality, and Medications
Pfeferman, M. B., Rashedi, S., Lip, G. Y. H., Weber, C., O’Donoghue, M. L., Nissen, S. E., Nicholls, S. J., Natarajan, P., Plutzky, J., Libby, P., et al. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2674-5114 · Cited by 14
Self-citationDiretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 98
Self-citationDietary Effects on Monocyte Phenotypes in Subjects With Hypertriglyceridemia and Metabolic Syndrome
Lian, Z., Perrard, X. D., Antony, A. K., Peng, X., Lu, X., Ni, J., Zhang, B., O’Brien, V., Saeed, A., Jia, X., et al. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.02.011 · Cited by 10
Kayani, T., Ahmad, B., Chang, R., Qian, F., Sahinoz, M., Rehan, M., Giaimo, A., Spatz, E. S., & Hu, J. (2024) · Pharmacoepidemiology · doi:10.3390/pharma3010009 · Cited by 16
Velidakis, N., Stachteas, P., Gkougkoudi, E., Papadopoulos, C. E., & Kadoglou, N. P. E. (2024) · Pharmaceuticals · doi:10.3390/ph17050568 · Cited by 9
The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance
Banerjee, Y., Patti, A. M., Giglio, R. V., Ciaccio, M., Vichithran, S., Faisal, S., Stoian, A. P., Rizvi, A. A., & Rizzo, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108517 · Cited by 8
Remnant cholesterol as a lipid-lowering target may have a long way to go
Cao, Y., Dou, K., & Li, J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad256 · Cited by 8
Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?
Béliard, S., Mourre, F., & Valéro, R. (2024) · Diabetologia · doi:10.1007/s00125-024-06100-z · Cited by 10
Arai, H., Yamashita, S., Araki, E., Yokote, K., Tanigawa, R., Saito, A., Yamasaki, S., Suganami, H., & Ishibashi, S. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64677 · Cited by 8
Self-citationTriglycerides and Cardiovascular Risk
Toth, P. P. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.07.027 · Cited by 9
Chang, Y. H., Shin, C. M., Han, K., Jung, J., Jin, E. H., Lim, J. H., Kang, S. J., Choi, Y. J., Yoon, H., Park, Y. S., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.753 · Cited by 10
Balling, M., Afzal, S., Varbo, A., Nordestgaard, B. G., & Langsted, A. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvae217 · Cited by 13
Self-citationDiabetes and Lipids: A Review and Update on Lipid Biomarkers and Cardiovascular Risk
Tsushima, Y., & Hatipoğlu, B. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.03.011 · Cited by 13
Владиславович, Е. М., Kukharchuk, V. V., Балахонова, Т. В., Gurevich, V. S., Сергиенко, И. В., Sokolov, A. A., Анатольевич, С. А., Иосифович, Ш. И., Ахмеджанов, Н. М., Барбараш, О. Л., et al. (2025) · Eurasian heart journal · doi:10.38109/2225-1685-2025-2-6-34 · Cited by 11
Zhang, C., Xie, Y., Zhou, J., Zhang, C., Xiang, Q., Zhong, Y., Xiao, J., Feng, J., Liao, B., Chen, X., et al. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70372 · Cited by 9
Jabbar, A. B. A., Naeem, U., Zulfiqar, K., Ahmed, S., Inam, M., Hinkamp, C. A., Minhas, A. M. K., Slipczuk, L. N., Krittanawong, C., Sahebkar, A., et al. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01376-x · Cited by 8
Toth, P. P., Ferrières, J., Waters, M., Mortensen, M. B., Lan, N. S. R., & Wong, N. D. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1220017 · Cited by 9
Novel Pharmacotherapies for Hyperlipidemia
Reamy, B. V., Ford, B., & Goodman, C. (2023) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2023.08.002 · Cited by 7
Abrahams, T., & Nicholls, S. J. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2292039 · Cited by 8
“While early studies with gemfibrozil showed cardiovascular benefit [41,42], subsequent studies with fenofibrate [43,44] and more recently the selective PPARα modulator, pemafibrate, did not [45].”
Result
Metadata
- Authors
- Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., Brinton, E. A., Eckel, R. H., Elam, M. B., Felicio, J. S., Ginsberg, H. N., Goudev, A., Ishibashi, S., Joseph, J., Kodama, T., Koenig, W., Leiter, L. A., Lorenzatti, A. J., Mankovsky, B., Marx, N., Nordestgaard, B. G., Páll, D., Ray, K. K., Santos, R. D., Soran, H., Susekov, A., Tendera, M., Yokote, K., Paynter, N. P., Buring, J. E., Libby, P., & Ridker, P. M.
- Affiliations
- From the Center for Cardiovascular Disease Prevention, Division of Preventive Medicine (A.D.P., R.J.G., J.G.M., E.S.Z., B.M.E., N.P.P., J.E.B., P.M.R) and the Division of Cardiovascular Medicine (B.M.E.,P.L., P.M.R.), Brigham and Women’s Hospital, the Division of Cardiovascular Medicine, Veteran Affairs Boston Health Care System (A.D.P., J.J.), and Kowa Pharma Development (R.O.) — all in Boston; University of Lille, Lille (J.-C.F.) and the Department of Neurology and Stroke Center, Paris Cité University, Paris (P.A.) — both in France; Kowa Research Institute, Morrisville, NC (S.E.C.); the Division of Lipidology, Department of Medicine, University of Cape Town, Cape Town, South Africa (D.J.B.); Utah Lipid Center, Salt Lake City (E.A.B.); the University of Colorado School of Medicine, Aurora (R.H.E.); the University of Tennessee Health Science Center, Memphis (M.B.E.); the Division of Endocrinology, Universitário Hospital João de Barros Barreto, Belém (J.S.F.), and the Heart Institute (InCor), University of ...
- Brigham and Women's Hospital (US)
- University of Copenhagen (DK)
- ORCID
- Everett, Brendan M.
- Amarenco, Pierre
- Blom, Dirk J.
- Brinton, Eliot A.
- Eckel, Robert H.
- Elam, Marshall B.
- Ginsberg, Henry N.
- Goudev, Assen
- Ishibashi, Shun
- Joseph, Jacob
- Kodama, Tatsuhiko
- Leiter, Lawrence A.
- Lorenzatti, Alberto J.
- Mankovsky, Boris
- Marx, Nikolaus
- Nordestgaard, Børge G.
- Páll, Dénes
- Ray, Kausik K.
- Santos, Raul D.
- Soran, Handrean
- Susekov, Andrey
- Yokote, Koutaro
- Paynter, Nina P.
- Buring, Julie E.
- Libby, Peter
- Ridker, Paul M
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-11-24
- Volume
- 387
- Issue
- 21
- Pages
- 1923-1934
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4308367139
- Semantic Scholar
- 2a5f509a3e50569b803a22d0dee824c145e73e75
- Cited by
- 749
- References
- 25
- Citations by year
- 2026: 153 · 2025: 185 · 2024: 191 · 2023: 208 · 2022: 10
- FWCI
- 142.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Kowa Research Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- pemafibrate, hypertriglyceridemia, type 2 diabetes, PPARα agonist, triglyceride lowering, cardiovascular risk reduction, cardiovascular events, HDL cholesterol, remnant cholesterol, apolipoprotein C-III, apolipoprotein B, VLDL cholesterol, renal adverse effects, venous thromboembolism, lipid-lowering therapy, statin intolerance
- MeSH terms
- Heart Disease Risk Factors, Hypolipidemic Agents, Benzoxazoles, Butyrates, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Humans, Hyperlipidemias, Cholesterol, HDL, Cholesterol, LDL, Risk Factors, Triglycerides, Hypertriglyceridemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors, PPAR alpha, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.